Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.84

+1.8%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4380)	7/31/2001 9:57:42 AM
From: rkrw	Read Replies (2) of 52153

<<It looks to me to be clearly better than straight Ritalin - a longer duration of action if nothing else, and hopefully easier titration of dosage.>> An issue is that the celg version will be going up against JNJ's extended release ritalin. The celg nda filed drug is not once-per-day. This could limit it's market potential. I'm not sure when the celg extended release isomer version will be nda filed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next